Ivabradina Generis

Ivabradine, the active ingredient in Ivabradina Generis, is an If channel inhibitor presented as a tablet for oral use. It reduces heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction. GNH USA supplies Ivabradina Generis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Generis acts on the cardiac If current to control heart rate in specific cardiovascular conditions. - Chronic stable angina pectoris: improves exercise tolerance and reduces the frequency of angina attacks. - Heart failure with reduced ejection fraction (NYHA II–III): lowers heart rate, helping to alleviate symptoms and improve functional capacity. - Coronary artery disease (as adjunct therapy): assists in heart‑rate control when beta‑blockers are unsuitable.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: excessively low heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Symptomatic atrial fibrillation. - Severe hypotension. - Syncope (fainting).

Ivabradina Generis requires careful patient assessment and monitoring. - Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiation. - Concomitant beta‑blocker use: avoid excessive heart‑rate reduction. - Liver impairment: dose adjustment may be needed. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Ivabradine may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce ivabradine exposure. - Concomitant use with other bradycardic agents (e.g., digoxin, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise ivabradine concentrations. - Verapamil: can enhance bradycardic effect. - Antihypertensives: monitor blood pressure and heart rate.